Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The aims of this study were to evaluate treatment responses and predictive factors for overall survival (OS) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) treated with iodine-125 (125I) brachytherapy.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Brachytherapy

Title: Brachytherapy

Publisher: Elsevier BV

ISSN (Electronic): 1873-1449

ISSN (Print): 1538-4721

Publication date (Electronic): November 24 2018

Volume: 18

Issue: 2

Affiliations

[1 ] Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, China.

[2 ] Department of Nuclear Medicine, Fujian Medical University Union Hospital, Fuzhou, China.

[3 ] Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, China. Electronic address: xhjrhjy@sohu.com.

Article

Publisher Item ID: S1538-4721(18)30424-0

DOI: 10.1016/j.brachy.2018.10.002

PubMed ID: 30467014

SO-VID: 50523b15-55b5-4424-af40-ca465710e7e3

History

Keywords: Brachytherapy,Hepatocellular carcinoma,Iodine-125,Portal vein

Data availability:

Keywords: Brachytherapy, Hepatocellular carcinoma, Iodine-125, Portal vein

Comments

Comment on this article

scite_

Cited by 3

See all cited by